Mallinckrodt PLC (NYSE:MNK) traded down 2% during mid-day trading on Friday . The stock traded as low as $65.85 and last traded at $66.19, with a volume of 374,478 shares. The stock had previously closed at $67.53.

Several equities research analysts have issued reports on the company. Piper Jaffray Cos. lifted their price objective on Mallinckrodt PLC from $97.00 to $102.00 and gave the stock an “overweight” rating in a report on Tuesday, May 3rd. Oppenheimer Holdings Inc. restated a “buy” rating on shares of Mallinckrodt PLC in a report on Wednesday, May 4th. Morgan Stanley restated a “buy” rating on shares of Mallinckrodt PLC in a report on Wednesday, April 27th. Mizuho lifted their price objective on Mallinckrodt PLC from $78.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, May 4th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Mallinckrodt PLC in a report on Tuesday, May 3rd. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $91.42.

The firm has a market capitalization of $7.27 billion and a P/E ratio of 16.69. The stock has a 50-day moving average price of $61.08 and a 200 day moving average price of $62.51.

Mallinckrodt PLC (NYSE:MNK) last announced its earnings results on Tuesday, May 3rd. The company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.29. The business had revenue of $918 million for the quarter, compared to the consensus estimate of $878.70 million. Mallinckrodt PLC’s revenue for the quarter was up 12.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.72 EPS. Equities research analysts expect that Mallinckrodt PLC will post $8.28 earnings per share for the current fiscal year.

In other news, CFO Matthew K. Harbaugh acquired 500 shares of Mallinckrodt PLC stock in a transaction on Tuesday, May 10th. The stock was bought at an average price of $59.37 per share, for a total transaction of $29,685.00. Following the transaction, the chief financial officer now owns 56,036 shares of the company’s stock, valued at $3,326,857.32. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Hugh M. O’neill acquired 1,653 shares of Mallinckrodt PLC stock in a transaction on Tuesday, May 10th. The stock was purchased at an average price of $60.99 per share, with a total value of $100,816.47. Following the transaction, the vice president now directly owns 15,623 shares in the company, valued at approximately $952,846.77. The disclosure for this purchase can be found here.

Several institutional investors recently modified their holdings of MNK. Nationwide Fund Advisors boosted its position in shares of Mallinckrodt PLC by 1.8% in the fourth quarter. Nationwide Fund Advisors now owns 34,985 shares of the company’s stock worth $2,611,000 after buying an additional 606 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Mallinckrodt PLC by 7.4% in the fourth quarter. New York State Common Retirement Fund now owns 372,509 shares of the company’s stock worth $27,800,000 after buying an additional 25,709 shares during the last quarter. Gamco Investors INC. ET AL bought a new position in shares of Mallinckrodt PLC during the fourth quarter worth about $1,161,000. Gabelli Funds LLC boosted its position in shares of Mallinckrodt PLC by 50.1% in the fourth quarter. Gabelli Funds LLC now owns 57,500 shares of the company’s stock worth $4,291,000 after buying an additional 19,200 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in shares of Mallinckrodt PLC by 3.2% in the fourth quarter. Vanguard Group Inc. now owns 10,007,770 shares of the company’s stock worth $746,880,000 after buying an additional 308,237 shares during the last quarter.

Mallinckrodt public limited company (Mallinckrodt) is engaged in the specialty pharmaceuticals and nuclear imaging business. The Company develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products, and nuclear imaging agents. The Company’s segments include Specialty Brands, Specialty Generics and Nuclear Imaging.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.